Abiprubart

Abiprubart is a humanized monoclonal IgG4 antibody with a stabilized, functionally silent Fc region that binds to CD40 and inhibits the CD40-CD154 (CD40 ligand) costimulatory interaction without lymphocyte depletion. It is designed to disrupt this key T-cell co-stimulatory signal, which is critical for B-cell maturation, immunoglobulin class switching, and type 1 immune responses. Abiprubart has been investigated primarily for autoimmune diseases such as Sjögren's disease (sicca syndrome) and rheumatoid arthritis, with additional exploration in other T-cell-dependent, B-cell-mediated conditions including focal segmental glomerulosclerosis (FSGS), pemphigus/pemphigoid, myasthenia gravis, graft versus host disease, systemic lupus erythematosus (SLE), type 1 diabetes, ulcerative colitis, lupus nephritis, hidradenitis suppurativa, transplant rejection (heart/pancreatic islet/kidney), and idiopathic thrombocytopenic purpura. The drug was developed by Kiniksa Pharmaceuticals following its origin at Primatope Therapeutics[1][2][3][5][6][7][8].